{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:12:50Z","timestamp":1791216770526,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100031366","name":"ERA-Net NEURON","doi-asserted-by":"publisher","award":["EudraCT Number: 2020-003650-77"],"award-info":[{"award-number":["EudraCT Number: 2020-003650-77"]}],"id":[{"id":"10.13039\/100031366","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Instituto Investigaci\u00f3n Carlos III","award":["EudraCT 2020-002639-31"],"award-info":[{"award-number":["EudraCT 2020-002639-31"]}]},{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-026-02393-0","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:13:33Z","timestamp":1778933613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Brain structural MRI changes before and after 6 months of preventive treatment with erenumab and onabotulinumtoxinA in migraine"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9257-898X","authenticated-orcid":false,"given":"Joana","family":"Rosell-Mirmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5525-0267","authenticated-orcid":false,"given":"Edoardo","family":"Caronna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3042-2007","authenticated-orcid":false,"given":"V\u00edctor J.","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7356-3769","authenticated-orcid":false,"given":"Deborah","family":"Pareto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5296-9401","authenticated-orcid":false,"given":"Alicia","family":"Alpuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2856-4134","authenticated-orcid":false,"given":"Marta","family":"Torres-Ferr\u00fas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5286-7605","authenticated-orcid":false,"given":"Eulalia","family":"Gin\u00e9-Cipr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2132-6750","authenticated-orcid":false,"given":"\u00c0lex","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0796-4702","authenticated-orcid":false,"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"2393_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0074-7742(","volume":"67","author":"PM Thompson","year":"2005","unstructured":"Thompson PM, Sowell ER, Gogtay N, Giedd JN, Vidal CN, Hayashi KM et al (2005) Structural MRI and Brain Development. Int Rev Neurobiol 67:285\u2013323. https:\/\/doi.org\/10.1016\/S0074-7742(05)67009-2. PubMed PMID: 16291026","journal-title":"Int Rev Neurobiol"},{"issue":"5","key":"2393_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1177\/0333102420974359","volume":"41","author":"P Pozo-Rosich","year":"2021","unstructured":"Pozo-Rosich P, Coppola G, Pascual J, Schwedt TJ (2021) How does the brain change in chronic migraine? Developing disease biomarkers. Cephalalgia 41(5):613\u2013630. https:\/\/doi.org\/10.1177\/0333102420974359","journal-title":"Cephalalgia"},{"key":"2393_CR3","doi-asserted-by":"publisher","unstructured":"Christensen RH, Ashina H, Al-Khazali HM, Zhang Y, Tolnai D, Poulsen AH et al (2024) Differences in cortical morphology in people with and without migraine. Neurology 102(9). https:\/\/doi.org\/10.1212\/WNL.0000000000209305","DOI":"10.1212\/WNL.0000000000209305"},{"issue":"14","key":"2393_CR4","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1177\/0333102411421025","volume":"31","author":"R Datta","year":"2011","unstructured":"Datta R, Detre JA, Aguirre GK, Cucchiara B (2011) Absence of changes in cortical thickness in patients with migraine. Cephalalgia 31(14):1452\u20131458. https:\/\/doi.org\/10.1177\/0333102411421025","journal-title":"Cephalalgia"},{"issue":"4","key":"2393_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0333102415588328","volume":"36","author":"B Bilgi\u00e7","year":"2016","unstructured":"Bilgi\u00e7 B, Kocaman G, Arslan AB, Noyan H, Sherifov R, Alkan A et al (2016) Volumetric differences suggest involvement of cerebellum and brainstem in chronic migraine. Cephalalgia 36(4):301\u2013308. https:\/\/doi.org\/10.1177\/0333102415588328","journal-title":"Cephalalgia"},{"issue":"3","key":"2393_CR6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/head.13012","volume":"57","author":"L Neeb","year":"2017","unstructured":"Neeb L, Bastian K, Villringer K, Israel H, Reuter U, Fiebach JB (2017) Structural Gray Matter Alterations in Chronic Migraine: Implications for a Progressive Disease? Headache: J Head Face Pain 57(3):400\u2013416. https:\/\/doi.org\/10.1111\/head.13012","journal-title":"Headache: J Head Face Pain"},{"issue":"5","key":"2393_CR7","doi-asserted-by":"publisher","first-page":"e210235","DOI":"10.1212\/WNL.0000000000210235","volume":"104","author":"S Schramm","year":"2025","unstructured":"Schramm S, B\u00f6rner-Schr\u00f6der C, Reichert M, Ramsch\u00fctz C, Androulakis XM, Ashina M et al (2025) Consensus Recommendations to Establish Reporting Standards in fMRI of Migraine: A Delphi Study. Neurology 104(5):e210235. https:\/\/doi.org\/10.1212\/WNL.0000000000210235. PubMed PMID: 39928906","journal-title":"Neurology"},{"key":"2393_CR8","doi-asserted-by":"publisher","unstructured":"Chaudhry BA, Younis S, Messina R, Garc\u00eda-Azor\u00edn D, Karsan N, Coppola G et al (2025) Cortical thickness studies in migraine: Current evidence and future directions. Cephalalgia 45(6). https:\/\/doi.org\/10.1177\/03331024251341204","DOI":"10.1177\/03331024251341204"},{"key":"2393_CR9","doi-asserted-by":"publisher","unstructured":"Puledda F, Sacco S, Diener HC, Ashina M, Al-Khazali HM, Ashina S et al (2024) International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia 44(8). https:\/\/doi.org\/10.1177\/03331024241252666","DOI":"10.1177\/03331024241252666"},{"key":"2393_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-333295","author":"E Caronna","year":"2024","unstructured":"Caronna E, Gallardo VJ, Egeo G, V\u00e1zquez MM, Castellanos CN, Membrilla JA, et al (2024) Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world. J Neurol Neurosurg Psychiatry. https:\/\/doi.org\/10.1136\/jnnp-2023-333295.jnnp-2023-333295.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"2393_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamaneurol.2024.0368","volume":"81","author":"P Pozo-Rosich","year":"2024","unstructured":"Pozo-Rosich P, Dolezil D, Paemeleire K, Stepien A, Stude P, Snellman J et al (2024) Early Use of Erenumab vs Nonspecific Oral Migraine Preventives. JAMA Neurol 81(5):461. https:\/\/doi.org\/10.1001\/jamaneurol.2024.0368","journal-title":"JAMA Neurol"},{"issue":"2","key":"2393_CR12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/ene.13523","volume":"25","author":"C Dom\u00ednguez","year":"2018","unstructured":"Dom\u00ednguez C, Pozo-Rosich P, Torres\u2010Ferr\u00fas M, Hern\u00e1ndez\u2010Beltr\u00e1n N, Jurado\u2010Cobo C, Gonz\u00e1lez\u2010Oria C et al (2018) OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study. Eur J Neurol 25(2):411\u2013416. https:\/\/doi.org\/10.1111\/ene.13523","journal-title":"Eur J Neurol"},{"key":"2393_CR13","doi-asserted-by":"publisher","unstructured":"Pozo-Rosich P, Caronna E, Sacco S, Peres MFP, Ashina S, \u00d6zge A et al (2025) Early treatment in migraine \u2013 A call to shift prevention from attacks to disease progression: A position statement from the International Headache Society. Cephalalgia 45(10). https:\/\/doi.org\/10.1177\/03331024251387721","DOI":"10.1177\/03331024251387721"},{"key":"2393_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/B978-0-12-823356-6.00011-1","volume":"198","author":"R Messina","year":"2023","unstructured":"Messina R, Filippi M (2023) What imaging has revealed about migraine and chronic migraine. Handb Clin Neurol 198:105\u2013116. https:\/\/doi.org\/10.1016\/B978-0-12-823356-6.00011-1. PubMed PMID: 38043956","journal-title":"Handb Clin Neurol"},{"key":"2393_CR15","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"key":"2393_CR16","unstructured":"Santos Lasaosa S, Pozo-Rosich P, Belv\u00eds Nieto R, Latorre Gonz\u00e1lez G (2020) Gonz\u00e1lez Oria C. Recomendaciones Diagn\u00f3stico Terap\u00e9uticas de la Sociedad Espa\u00f1ola de Neurolog\u00eda 2020. SEN"},{"issue":"7","key":"2393_CR17","doi-asserted-by":"publisher","first-page":"117012","DOI":"10.1016\/j.neuroimage.2020.117012","volume":"219","author":"L Henschel","year":"2020","unstructured":"Henschel L, Conjeti S, Estrada S, Diers K, Fischl B, Reuter M (2020) FastSurfer - A fast and accurate deep learning based neuroimaging pipeline. NeuroImage 219(7):117012. https:\/\/doi.org\/10.1016\/j.neuroimage.2020.117012. PubMed PMID: 32526386","journal-title":"NeuroImage"},{"issue":"3","key":"2393_CR18","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.neuroimage.2006.01.021","volume":"31","author":"RS Desikan","year":"2006","unstructured":"Desikan RS, S\u00e9gonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D et al (2006) An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. NeuroImage 31(3):968\u2013980. https:\/\/doi.org\/10.1016\/j.neuroimage.2006.01.021","journal-title":"NeuroImage"},{"issue":"6","key":"2393_CR19","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.25011\/cim.v39i6.27495","volume":"39","author":"BT Demir","year":"2016","unstructured":"Demir BT, Bayram NA, Ayturk Z, Erdamar H, Seven P, Calp A et al (2016) Structural Changes in the Cerebrum, Cerebellum and Corpus Callosum in Migraine Patients. Clin Invest Med 39(6):S21\u2013S26. https:\/\/doi.org\/10.25011\/cim.v39i6.27495","journal-title":"Clin Invest Med"},{"issue":"4","key":"2393_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1177\/0333102419885375","volume":"40","author":"P Pozo-Rosich","year":"2020","unstructured":"Pozo-Rosich P, Torres-Ferrus M (2020) When does chronic migraine strike? Cephalalgia 40(4):411\u2013412. https:\/\/doi.org\/10.1177\/0333102419885375","journal-title":"Cephalalgia"},{"key":"2393_CR21","unstructured":"Agencia espa\u00f1ola de medicamentos y productos sanitarios (AEMPS) (2019) - Ministerio de Sanidad C y BSocialG de E. Informe de Posicionamiento Terap\u00e9utico de erenumab (Aimovig\u00ae) en la profilaxis de migra\u00f1a"},{"issue":"10","key":"2393_CR22","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00234-020-02451-7","volume":"62","author":"A Aldemir","year":"2020","unstructured":"Aldemir A, Yucel K, G\u00fcven H, Kama\u015fak B, Dilli A, Acer N et al (2020) Structural neuroimaging findings in migraine patients with restless legs syndrome. Neuroradiology 62(10):1301\u20131313. https:\/\/doi.org\/10.1007\/s00234-020-02451-7","journal-title":"Neuroradiology"},{"issue":"5","key":"2393_CR23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00234-019-02357-z","volume":"62","author":"J Blaauw","year":"2020","unstructured":"Blaauw J, Meiners LC (2020) The splenium of the corpus callosum: embryology, anatomy, function and imaging with pathophysiological hypothesis. Neuroradiology 62(5):563\u2013585. https:\/\/doi.org\/10.1007\/s00234-019-02357-z","journal-title":"Neuroradiology"},{"issue":"11","key":"2393_CR24","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1093\/pm\/pnaa271","volume":"21","author":"\u00c1 Planchuelo-G\u00f3mez","year":"2020","unstructured":"Planchuelo-G\u00f3mez \u00c1, Garc\u00eda-Azor\u00edn D, Guerrero \u00c1L, Rodr\u00edguez M, Aja-Fern\u00e1ndez S, de Luis-Garc\u00eda R (2020) Gray Matter Structural Alterations in Chronic and Episodic Migraine: A Morphometric Magnetic Resonance Imaging Study. Pain Med 21(11):2997\u20133011. https:\/\/doi.org\/10.1093\/pm\/pnaa271","journal-title":"Pain Med"},{"issue":"1","key":"2393_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s10194-021-01289-5","volume":"22","author":"M Torres-Ferrus","year":"2021","unstructured":"Torres-Ferrus M, Pareto D, Gallardo VJ, Cuberas-Borr\u00f3s G, Alpuente A, Caronna E et al (2021) Cortical metabolic and structural differences in patients with chronic migraine. An exploratory 18FDG-PET and MRI study. J Headache Pain 22(1):75. https:\/\/doi.org\/10.1186\/s10194-021-01289-5","journal-title":"J Headache Pain"},{"issue":"1","key":"2393_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-023-01588-z","volume":"24","author":"T Yin","year":"2023","unstructured":"Yin T, Lan L, Tian Z, Li Z, Liu M, Gao Y et al (2023) Parahippocampus hypertrophy drives gray matter morphological alterations in migraine patients without aura. J Headache Pain 24(1):53. https:\/\/doi.org\/10.1186\/s10194-023-01588-z","journal-title":"J Headache Pain"},{"issue":"2","key":"2393_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11916-018-0668-6","volume":"22","author":"HY Liu","year":"2018","unstructured":"Liu HY, Chou KH, Chen WT (2018) Migraine and the Hippocampus. Curr Pain Headache Rep 22(2):13. https:\/\/doi.org\/10.1007\/s11916-018-0668-6","journal-title":"Curr Pain Headache Rep"},{"key":"2393_CR28","doi-asserted-by":"publisher","unstructured":"Hubbard CS, Becerra L, Smith JH, DeLange JM, Smith RM, Black DF et al (2016) Brain changes in responders vs. non-responders in chronic migraine: markers of disease reversal. Front Hum Neurosci 10. https:\/\/doi.org\/10.3389\/fnhum.2016.00497","DOI":"10.3389\/fnhum.2016.00497"},{"issue":"1","key":"2393_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-025-02051-x","volume":"26","author":"D Liu","year":"2025","unstructured":"Liu D, Li M, Jiang H, Mi Y, Xu X, Zhou Y et al (2025) Regional and whole-brain neurofunctional alterations during pain empathic processing of physical but not affective pain in migraine patients. J Headache Pain 26(1):137. https:\/\/doi.org\/10.1186\/s10194-025-02051-x","journal-title":"J Headache Pain"},{"key":"2393_CR30","doi-asserted-by":"publisher","unstructured":"Hubbard CS, Khan SA, Keaser ML, Mathur VA, Goyal M, Seminowicz DA (2014) Altered brain structure and function correlate with disease severity and pain catastrophizing in migraine patients. eNeuro 1(1):ENEURO0006\u2013142014. https:\/\/doi.org\/10.1523\/ENEURO.0006-14.2014","DOI":"10.1523\/ENEURO.0006-14.2014"},{"issue":"1","key":"2393_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.brainresrev.2010.05.005","volume":"65","author":"EA Moulton","year":"2010","unstructured":"Moulton EA, Schmahmann JD, Becerra L, Borsook D (2010) The cerebellum and pain: Passive integrator or active participator? Brain Res Rev 65(1):14\u201327. https:\/\/doi.org\/10.1016\/j.brainresrev.2010.05.005","journal-title":"Brain Res Rev"},{"issue":"7","key":"2393_CR32","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.cortex.2009.06.009","volume":"46","author":"D Timmann","year":"2010","unstructured":"Timmann D, Drepper J, Frings M, Maschke M, Richter S, Gerwig M et al (2010) The human cerebellum contributes to motor, emotional and cognitive associative learning. A review. Cortex 46(7):845\u2013857. https:\/\/doi.org\/10.1016\/j.cortex.2009.06.009","journal-title":"Cortex"},{"issue":"2","key":"2393_CR33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/0333102416643527","volume":"37","author":"H Koppen","year":"2017","unstructured":"Koppen H, Boele HJ, Palm-Meinders IH, Koutstaal BJ, Horlings CG, Koekkoek BK et al (2017) Cerebellar function and ischemic brain lesions in migraine patients from the general population. Cephalalgia 37(2):177\u2013190. https:\/\/doi.org\/10.1177\/0333102416643527","journal-title":"Cephalalgia"},{"issue":"11","key":"2393_CR34","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1177\/0333102417752120","volume":"38","author":"L Kros","year":"2018","unstructured":"Kros L, Angueyra Aristiz\u00e1bal CA, Khodakhah K (2018) Cerebellar involvement in migraine. Cephalalgia 38(11):1782\u20131791. https:\/\/doi.org\/10.1177\/0333102417752120","journal-title":"Cephalalgia"},{"key":"2393_CR35","doi-asserted-by":"publisher","first-page":"103531","DOI":"10.1016\/j.nicl.2023.103531","volume":"40","author":"E Szabo","year":"2023","unstructured":"Szabo E, Ashina S, Melo-Carrillo A, Bolo NR, Borsook D, Burstein R (2023) Peripherally acting anti-CGRP monoclonal antibodies alter cortical gray matter thickness in migraine patients: A prospective cohort study. Neuroimage Clin 40:103531. https:\/\/doi.org\/10.1016\/j.nicl.2023.103531","journal-title":"Neuroimage Clin"},{"key":"2393_CR36","doi-asserted-by":"publisher","unstructured":"Ziegeler C, Mehnert J, Asmussen K, May A (2020) Central effects of erenumab in migraine patients. Neurology 95(20). https:\/\/doi.org\/10.1212\/WNL.0000000000010740","DOI":"10.1212\/WNL.0000000000010740"},{"key":"2393_CR37","doi-asserted-by":"publisher","unstructured":"Basedau H, Sturm LM, Mehnert J, Peng KP, Schellong M, May A (2022) Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target \u2013 an fMRI study. Elife 11. https:\/\/doi.org\/10.7554\/eLife.77146","DOI":"10.7554\/eLife.77146"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-026-02393-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02393-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02393-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T03:37:10Z","timestamp":1783568230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-026-02393-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2393"],"URL":"https:\/\/doi.org\/10.1186\/s10194-026-02393-0","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study belongs to the MAB Registry and includes participants from phase IV clinical trials EudraCT Number: 2019-002224-32, REEC ID: 2020-002639-31, and REEC ID: 2020-003650-77, and was approved by the Vall d\u2019Hebron Ethics Committee (PR(AG)53\/2017). All patients provided written informed consent that was obtained according to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"In relation to this paper, the authors declared the following potential conflicts of interest: JR-M has nothing to disclose. EC has received honoraria from Novartis, Chiesi, Lundbeck, MedScape, Lilly, Organon, Teva and Dr. Reddy\u2019s; his salary has been partially funded by R\u00edo Hortega grant Acci\u00f3n Estrat\u00e9gica en Salud 2017\u20132020 from Instituto de Salud Carlos III (CM20\/00217) and Juan Rod\u00e9s fellowship, Subprograma Estatal de Incorporaci\u00f3n de la Acci\u00f3n Estrat\u00e9gica en Salud 2023 (JR23\/00065). He is a junior editor for Cephalalgia. VJG has nothing to disclose. DP has nothing to disclose. AA has received honoraria from Allergan-AbbVie, Novartis, Chiesi. MT-F has received honoraria from Allergan-AbbVie, Novartis, Chiesi and Teva. EG-C has received honoraria for participation in medical education activities from AbbVie, Eli Lilly, Organon, Novartis, Teva, Lundbeck and Dr Reddy\u2019s. Additionally, the author has received consulting fees from AbbVie, and Lundbeck. EG-C has also received research grants from Sociedad Espa\u00f1ola de Enfermer\u00eda Neurol\u00f3gica. AR serves\/ed on scientific advisory boards for Novartis, Sanofi-Genzyme, Synthetic MR, TensorMedical, Roche, and Biogen, and has received speaker honoraria from Bayer, Sanofi-Genzyme, Merck-Serono, Teva Pharmaceutical Industries Ltd, Novartis, Roche, Bristol-Myers and Biogen, is CMO and co-founder of TensorMedical, and receives research support from Fondo de Investigaci\u00f3n en Salud (PI19\/00950 and PI22\/01589) from Instituto de Salud Carlos III, Spain. PP-R has received honoraria in the last 3 years, as a consultant and speaker from AbbVie, Almirall, Dr. Reddy\u2019s, Eli Lilly, Lundbeck, Medscape, Organon, Pfizer, Novartis and Teva Pharmaceuticals. Her research group has received research grants from AbbVie, AGAUR, EraNET Neuron, FEDER RIS3CAT, Instituto Investigaci\u00f3n Carlos III, MICINN, PERIS; and has received funding for clinical trials from AbbVie, Amgen, Biohaven, Eli Lilly, Ipsen, Lundbeck, Novartis, Pfizer, and Teva. PP-R does not own stocks from any pharmaceutical company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}